Leprosy
Tom Bradley
Child with Leprosy symptoms
© Credits
Leprosy

Leprosy in SEARO

What is leprosy?

Leprosy, also known as Hansen’s disease, is a chronic infectious disease caused by Mycobacterium leprae. The disease mainly affects the skin, the peripheral nerves, mucosal surfaces of the upper respiratory tract and the eyes. Leprosy is known to occur at all ages ranging from early infancy to very old age. Leprosy is curable and early treatment averts most disabilities.

Transmission

The exact mechanism of transmission of leprosy is not known. At least until recently, the most widely held belief was that the disease was transmitted by contact between cases of leprosy and healthy persons. More recently the possibility of transmission by the respiratory route is gaining ground. There are also other possibilities such as transmission through insects which cannot be completely ruled out.
Leprosy control

Seeking skin lesions, Brazil, 2015 ©WHO/PAHO

Signs/symptoms and diagnosis

Clinical signs are easy to observe. In a country or area with a high incidence of leprosy, an individual should be regarded as having leprosy if he or she shows ONE of the following cardinal signs:

  • skin lesion consistent with leprosy and with definite sensory loss, with or without thickened nerves
  • positive skin smears

The skin lesion can be single or multiple, usually less pigmented than the surrounding normal skin. Sometimes the lesion is reddish or copper-coloured. A variety of skin lesions may be seen but macules (flat), papules (raised), or nodules are common. Sensory loss is a typical feature of leprosy. The skin lesion may show loss of sensation to pin pick and/or light touch. Thickened nerves, mainly peripheral nerve trunks constitute another feature of leprosy. A thickened nerve is often accompanied by other signs as a result of damage to the nerve. These may be loss of sensation in the skin and weakness of muscles supplied by the affected nerve. In the absence of these signs, nerve thickening by itself, without sensory loss and/or muscle weakness is often not a reliable sign of leprosy.

Leprosy can be classified on the basis of clinical manifestations and skin smear results. In the classification based on skin smears, patients showing negative smears at all sites are said to have paucibacillary leprosy (PB), while those showing positive smears at any site are said to have multibacillary leprosy (MB).

Treatment

Leprosy is curable with a combination of drugs known as multidrug therapy (MDT), as the treatment of leprosy with only one anti leprosy drug (monotherapy) will result in development of drug resistance to that drug. The combination of drugs used in the MDT depends on the classification of the disease. Rifampicin, the most important anti leprosy medicine, is included in the treatment of both types of leprosy. For the treatment of patients with multibacillary leprosy, WHO recommends a combination of rifampicin, clofazimine and dapsone; for patients with paucibacillary leprosy, MDT uses a combination of rifampicin and dapsone.

-

Publications

All →
DHIS2-based leprosy/Hansen disease Elimination Monitoring Tool (‎LEMT)‎ – Standard operating procedures

The Leprosy Elimination Monitoring Tool (LEMT) has been developed based on the Leprosy Elimination Framework1 in order to promote: a standard way to...

Interruption of transmission and elimination of leprosy disease – Technical guidance - thumbnail

This document provides technical guidance on concepts, definitions, indicators, criteria, milestones and tools to assist leprosy programmes in their journey...

Leprosy elimination monitoring tool thumbnail

The Leprosy Elimination Monitoring Tool (LEMT) has been developed based on the Leprosy Elimination Framework. Promote a standard way to monitor progress...

Leprosy Programme and Transmission Assessment thumbnail

The Leprosy Programme and Transmission Assessment (LPTA) is an activity that is carried out by internal teams towards the end of Phase 1 (see Leprosy Elimination...

HQ Publications

A guide for surveillance of antimicrobial resistance in leprosy: 2017 update

The emergence of drug resistance is a concern and a threat for many infectious disease intervention programmes, especially those that have secondary prevention...

Monitoring and Evaluation Guide. Global Leprosy Strategy 2016–2020. Accelerating towards a leprosy-free world

This Monitoring & Evaluation Guide is the third document on the Global Leprosy Strategy 2016–2020 “Accelerating towards a leprosy-free...

Global Leprosy Strategy 2016−2020: Accelerating towards a leprosy-free world

The Global Leprosy Strategy 2016-2020 "Accelerating towards a leprosy-free world" was developed through a series of consultations with various stakeholders...

Operational Manual 2016 – Global Leprosy Strategy 2016−2020. Accelerating towards a leprosy-free world

The “Global Leprosy Strategy 2016–2020, Accelerating towards a leprosy-free world”, was officially launched on 20 April 2016. Its overall...